Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 5;8(8):CD011625.
doi: 10.1002/14651858.CD011625.pub3.

Interventions for preventing postpartum constipation

Eunice B Turawa  1   2 , Alfred Musekiwa  3 , Anke C Rohwer  4
Affiliations

Interventions for preventing postpartum constipation

Eunice B Turawa et al. Cochrane Database Syst Rev. .

Abstract

Background: Postpartum constipation, with symptoms, such as pain or discomfort, straining, and hard stool, is a common condition affecting mothers. Haemorrhoids, pain at the episiotomy site, effects of pregnancy hormones, and haematinics used in pregnancy can increase the risk of postpartum constipation. Eating a high-fibre diet and increasing fluid intake are usually encouraged. Although laxatives are commonly used in relieving constipation, the effectiveness and safety of available interventions for preventing postpartum constipation should be ascertained. This is an update of a review first published in 2015.

Objectives: To evaluate the effectiveness and safety of interventions for preventing postpartum constipation.

Search methods: We searched Cochrane Pregnancy and Childbirth's Trials Register, and two trials registers ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (7 October 2019), and screened reference lists of retrieved trials.

Selection criteria: We considered all randomised controlled trials (RCTs) comparing any intervention for preventing postpartum constipation versus another intervention, placebo, or no intervention in postpartum women. Interventions could include pharmacological (e.g. laxatives) and non-pharmacological interventions (e.g. acupuncture, educational and behavioural interventions). Quasi-randomised trials and cluster-RCTs were eligible for inclusion; none were identified. Trials using a cross-over design were not eligible.

Data collection and analysis: Two review authors independently screened the results of the search to select potentially relevant trials, extracted data, assessed risk of bias, and the certainty of the evidence, using the GRADE approach. We did not pool results in a meta-analysis, but reported them per study.

Main results: We included five trials (1208 postpartum mothers); three RCTs and two quasi-RCTs. Four trials compared a laxative with placebo; one compared a laxative plus a bulking agent versus the same laxative alone, in women who underwent surgical repair of third degree perineal tears. Trials were poorly reported, and four of the five trials were published over 40 years ago. We judged the risk of bias to be unclear for most domains. Overall, we found a high risk of selection and attrition bias. Laxative versus placebo We included four trials in this comparison. Two of the trials examined the effects of laxatives that are no longer used; one has been found to have carcinogenic properties (Danthron), and the other is not recommended for lactating women (Bisoxatin acetate); therefore, we did not include their results in our main findings. None of the trials included in this comparison assessed our primary outcomes: pain or straining on defecation, incidence of postpartum constipation, or quality of life; or many of our secondary outcomes. A laxative (senna) may increase the number of women having their first bowel movement within 24 hours after delivery (risk ratio (RR) 2.90, 95% confidence interval (CI) 2.24 to 3.75; 1 trial, 471 women; low-certainty evidence); may have little or no effect on the number of women having their first bowel movement on day one after delivery (RR 0.94, 95% CI 0.72 to 1.22; 1 trial, 471 women; very low-certainty evidence); may reduce the number of women having their first bowel movement on day two (RR 0.23, 95% CI 0.11 to 0.45; 1 trial, 471 women; low-certainty evidence); and day three (RR 0.05, 95% CI 0.00 to 0.89; 1 trial, 471 women; low-certainty evidence); and may have little or no effect on the number of women having their first bowel movement on day four after delivery (RR 0.22, 95% CI 0.03 to 1.87; 1 trial, 471 women; very low-certainty evidence), but some of the evidence is very uncertain. Adverse effects were poorly reported. Low-certainty evidence suggests that the laxative (senna) may increase the number of women experiencing abdominal cramps (RR 4.23, 95% CI 1.75 to 10.19; 1 trial, 471 women). Very low-certainty evidence suggests that laxatives taken by the mother may have little or no effect on loose stools in the baby (RR 0.62, 95% CI 0.16 to 2.41; 1 trial, 281 babies); or diarrhoea (RR 2.46, 95% CI 0.23 to 26.82; 1 trial, 281 babies). Laxative plus bulking agent versus laxative only Very low-certainty evidence from one trial (147 women) suggests no evidence of a difference between these two groups of women who underwent surgical repair of third degree perineal tears; only median and range data were reported. The trial also reported no evidence of a difference in the incidence of postpartum constipation (data not reported), but did not report on quality of life. Time to first bowel movement was reported as a median (range); very low-certainty evidence suggests little or no difference between the two groups. A laxative plus bulking agent may increase the number of women having any episode of faecal incontinence during the first 10 days postpartum (RR 1.81, 95% CI 1.01 to 3.23; 1 trial, 147 women; very low-certainty evidence). The trial did not report on adverse effects of the intervention on babies, or many of our secondary outcomes.

Authors' conclusions: There is insufficient evidence to make general conclusions about the effectiveness and safety of laxatives for preventing postpartum constipation. The evidence in this review was assessed as low to very low-certainty evidence, with downgrading decisions based on limitations in study design, indirectness and imprecision. We did not identify any trials assessing educational or behavioural interventions. We identified four trials that examined laxatives versus placebo, and one that examined laxatives versus laxatives plus stool bulking agents. Further, rigorous trials are needed to assess the effectiveness and safety of laxatives during the postpartum period for preventing constipation. Trials should assess educational and behavioural interventions, and positions that enhance defecation. They should report on the primary outcomes from this review: pain or straining on defecation, incidence of postpartum constipation, quality of life, time to first bowel movement after delivery, and adverse effects caused by the intervention, such as: nausea or vomiting, pain, and flatus.

PubMed Disclaimer

Conflict of interest statement

Eunice B Turawa: is partly supported by the Research, Evidence and Development Initiative (READ‐It) project (project number 300342‐104). READ‐It is funded by aid from the UK government; however, the views expressed do not necessarily reflect the UK government’s official policies.

Alfred Musekiwa: is partly supported by the Research, Evidence and Development Initiative (READ‐It) project (project number 300342‐104). READ‐It is funded by aid from the UK government; however, the views expressed do not necessarily reflect the UK government’s official policies.

Anke C Rohwer: is partly supported by the Research, Evidence and Development Initiative (READ‐It) project (project number 300342‐104). READ‐It is funded by aid from the UK government; however, the views expressed do not necessarily reflect the UK government’s official policies. This DFID grant aimed at ensuring the best possible systematic reviews, particularly Cochrane Reviews, are completed on topics relevant to the poor, particularly women, in low‐ and middle‐income countries. DFID does not participate in the selection of topics, in the conduct of the review, or in the interpretation of findings.

Figures

1
1
Study flow diagram
2
2
'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies
3
3
'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study
1.1
1.1. Analysis
Comparison 1: Laxative versus placebo, Outcome 1: Number of women with first bowel movement within 24 hours after delivery
1.2
1.2. Analysis
Comparison 1: Laxative versus placebo, Outcome 2: Number of women with first bowel movement on day 1 after delivery
1.3
1.3. Analysis
Comparison 1: Laxative versus placebo, Outcome 3: Number of women with first bowel movement on day 2 after delivery
1.4
1.4. Analysis
Comparison 1: Laxative versus placebo, Outcome 4: Number of women with first bowel movement on day 3 after delivery
1.5
1.5. Analysis
Comparison 1: Laxative versus placebo, Outcome 5: Number of women with first bowel movement on day 4 after delivery
1.6
1.6. Analysis
Comparison 1: Laxative versus placebo, Outcome 6: Stool consistency ‐ loose or watery stools
1.7
1.7. Analysis
Comparison 1: Laxative versus placebo, Outcome 7: Number of postpartum enemas given
1.8
1.8. Analysis
Comparison 1: Laxative versus placebo, Outcome 8: Number of women receiving suppositories or enemas
1.9
1.9. Analysis
Comparison 1: Laxative versus placebo, Outcome 9: Number of women having 2 or more bowel movements per day
1.10
1.10. Analysis
Comparison 1: Laxative versus placebo, Outcome 10: Number of days on which a bowel movement occurred
1.11
1.11. Analysis
Comparison 1: Laxative versus placebo, Outcome 11: Adverse effects: women with abdominal cramps
1.12
1.12. Analysis
Comparison 1: Laxative versus placebo, Outcome 12: Adverse effects on the baby
2.1
2.1. Analysis
Comparison 2: Laxative plus bulking agent versus laxative alone, Outcome 1: Faecal incontinence during first 10 postpartum days
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

Diamond 1968 {published data only}
    1. Diamond RA, Gall SA, Spellacy WN. Bisoxatin acetate as a postpartum oral laxative: a random double blind controlled experiment in 106 subjects. Lancet 1968;88:16-7. - PubMed
Eogan 2007 {published data only}
    1. Eogan M, Daly L, Behan M, O'Connell PR, O'Herlihy C. Randomised clinical trial of a laxative alone versus a laxative and a bulking agent after primary repair of obstetric anal sphincter injury. BJOG 2007;114(6):736-40. - PubMed
Mundow 1975 {published data only}
    1. Mundow L. Danthron/poloxalkol and placebo in puerperal constipation. British Journal of Clinical Practice 1975;29:95-6. - PubMed
Shelton 1980 {published data only}
    1. Shelton MG. Standardised senna in the management of constipation in the puerperium ‒ a clinical trial. South African Medical Journal 1980;57:78-80. - PubMed
Zuspan 1960 {published data only}
    1. Zuspan FP. A double-blind laxative study on postpartum patients. American Journal of Obstetrics and Gynecology 1960;80:548-50. - PubMed

References to studies excluded from this review

ChiCTR1900023067 {published data only}
    1. ChiCTR1900023067. Transcutaneous Electrical Acustimulation on the morphology and function of pelvic floor in patients with postpartum constipation by neuropeptide Y pathway: a prospective study. www.chictr.org.cn/showproj.aspx?proj=38857 (first received 9 May 2019).
Liu 2009 {published data only}
    1. Liu N, Mao L, Sun X, Liu L, Yao P, Chen B. The effect of health and nutrition education intervention on women's postpartum beliefs and practices: a randomized controlled trial. BMC Public Health 2009;9:45. - PMC - PubMed
Mahony 2004 {published data only}
    1. Mahony R, Behan M, O'Herlihy C, O'Connell PR. Randomized, clinical trial of bowel confinement vs. laxative use after primary repair of a third-degree obstetric anal sphincter tear. Diseases of the Colon and Rectum 2004;47(1):12-7. - PubMed
    1. Mahony R, Behan M, OConnell PR, OHerlihy C. Randomized clinical trial of bowel confinement versus laxative use following primary repair of a third degree obstetric anal sphincter tear. American Journal of Obstetrics and Gynecology 2002;187(6 Pt 2):S166.
Sakai 2015 {published data only}
    1. Sakai T, Kubota H, Gawad A, Gheyle L, Ramael S, Oishi K. Effect of fermented milk containing Lactobacillus casei strain Shirota on constipation-related symptoms and haemorrhoids in women during puerperium. Beneficial Microbes 2015;6(3):253-62. - PubMed

References to ongoing studies

IRCT20190427043386N1 {published data only}
    1. IRCT20190427043386N1. The effect of Kegel exercises for prevention and treatment of constipation and flatulence in antenatal and postnatal. www.irct.ir/trial/39108 (first received 14 May 2015).

Additional references

Aksu 2017
    1. Aksu S, Varol FG, Hotun Sahin N. Long-term postpartum health problems in Turkish women: prevalence and associations with self-rated health. Contemporary Nurse 2017;53(2):167-81. - PubMed
Alonso‐Coello 2005
    1. Alonso-Coello P, Guyatt GH, Heels-Ansdell D, Johanson JF, Lopez-Yarto M, Mills E, et al. Laxatives for the treatment of hemorrhoids. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No: CD004649. [DOI: 10.1002/14651858.CD004649.pub2] - DOI - PMC - PubMed
Andrews 2011
    1. Andrews CN, Storr M. The pathophysiology of chronic constipation. Canadian Journal of Gastroenterology 2011;25:16B-21B. - PMC - PubMed
Balch 2010
    1. Balch PA. Prescription for Nutritional Healing: a Practical A-to-Z Reference to Drug-free Remedies using Vitamins, Minerals, Herbs & Food Supplements. 5th edition. New York: Penguin, 2010.
Barth 1984
    1. Barth JH, Reshad H, Darley CR, Gibson JR. A cutaneous complication of Dorbanex therapy. Clinical and Experimental Dermatology 1984;9(1):95-6. [DOI: 10.1111/j.1365-2230.1984.tb00763.x] - DOI - PubMed
Borders 2006
    1. Borders N. After the afterbirth: a critical review of postpartum health relative to method of delivery. Journal of Midwifery & Women's Health 2006;51(4):242-8. - PubMed
Brown 1998
    1. Brown S, Lumley J. Maternal health after childbirth: results of an Australian population based survey. BJOG 1998;105(2):156-61. - PubMed
CADTH 2014
    1. Anonymous. Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: A review of the clinical effectiveness.. In: [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2014. - PubMed
Candy 2011
    1. Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No: CD003448. [DOI: 10.1002/14651858.CD003448.pub3] - DOI - PubMed
Cappell 2017
    1. Cappell J, Pukall CF. Clinical profile of persistent genito-pelvic postpartum pain. Midwifery 2017;1(50):125-32. - PubMed
Cheng 2006
    1. Cheng CY, Fowles ER, Walker LO. Postpartum maternal health care in the United States: a critical review. Journal of Prenatal Education 2006;15(3):34-42. - PMC - PubMed
Davies 2003
    1. Davies GA, Wolfe LA, Mottola MF, MacKinnon C, Arsenault MY, Bartellas E, Cargill Y, Gleason T, Iglesias S, Klein M, Martel MJ. Exercise in pregnancy and the postpartum period. Journal of Obstetrics and Gynaecology Canada 2003;(6):516-29. - PubMed
de Groot 2018
    1. Groot N, Birnie E, Vermolen JH, Dorscheidt JJA, Bonsel GJ. The prevalence of adverse postnatal outcomes for mother and infant in the Netherlands. PLoS ONE 2018;13(9):e0202960. - PMC - PubMed
Drossman 2016
    1. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology 2016;150(6):1262-79. - PubMed
Fakheri 2019
    1. Fakheri RJ, Volpicelli FM. Things we do for no reason: prescribing docusate for constipation in hospitalized adults. Journal of Hospital Medicine 2019;14(2):110-3. - PubMed
Gordon 2012
    1. Gordon, M, MacDonald, J K, Parker, C E, Akobeng, A K, & Thomas, A G. Osmotic and stimulant laxatives for the management of childhood constipation. Cochrane Database of Systematic Reviews 2016, Issue 8. Art. No: CD009118. [DOI: 10.1002/14651858.CD009118.pub2] - DOI - PMC - PubMed
Gozum 2005
    1. Gozum S, Kilic D. Health problems related to early discharge of Turkish women. Midwifery 2005;21(4):371-8. - PubMed
GRADE Handbook
    1. Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.
Higgins 2004
    1. Higgins PDR, Johanson JF. Epidemiology of constipation in North America: a systematic review. American Journal of Gastroenterology 2004;4:750-9. - PubMed
Higgins 2011
    1. Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Jia 2009
    1. Jia G, Meng M-B, Huang Z-W, Qing X, Lei W, Yang X-N, et al. Treatment of functional constipation with the Yun-chang capsule. Journal of Gastroenterology and Hepatology 2009;25(3):487-93. - PubMed
Kabakian‐Khasholian 2014
    1. Kabakian-Khasholian T, Shayboub R, Ataya A. Health after childbirth: patterns of reported postpartum morbidity from Lebanon. Women and Birth 2014;27(1):15-20. - PubMed
Lee‐Robichaud 2010
    1. Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database of Systematic Reviews 2010, Issue 7. Art. No: CD007570. [DOI: 10.1002/14651858.CD007570.pub2] - DOI - PubMed
Lewis 1997
    1. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scandinavian Journal of Gastroenterology 1997;32(9):920-4. - PubMed
Liberati 2009
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700. - PMC - PubMed
Lin 2009
    1. Lin LW, Fu YT, Dunning T, Zhang AL, Ho TH, Duke M, et al. Efficacy of traditional Chinese medicine for the management of constipation: a systematic review. Journal of Alternative and Complementary Medicine (New York, N.Y.) 2009;15(12):1335-46. - PubMed
MacArthur 1991
    1. MacArthur C, Lewis M, Knox EG. Health after childbirth. BJOG 1991;98(12):1193-5. - PubMed
MacMillan 2016
    1. MacMillan TE, Kamali R, Cavalcanti RB. Missed opportunity to deprescribe: docusate for constipation in medical inpatients. American Journal of Medicine 2016;129(9):1001.e1-7. - PubMed
Mottola 2002
    1. Mottola MF. Exercise in the postpartum period: practical applications. Current Sports Medicine Reports 2002;1(6):362-8. - PubMed
Mugie 2011
    1. Mugie SM, Beninga MA, Lorenzo CD. Epidemiology of constipation in children and adults. Best Practice & Research. Clinical Gastroenterology 2011;25(1):3-18. - PubMed
National Toxicology Program 2016
    1. National Toxicology Program. Report on Carcinogens Danthron: 14th Report on Carcinogens. https://ntp.niehs.nih.gov/go/roc 2016.
NIH‐NIDDK 2018
    1. National Institute of Health: National Institute of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK). Constipation. www.niddk.nih.gov/health-information/digestive-diseases/constipation May 2018.
Omega Pharma 2016
    1. Omega Pharma Blegium NV. Wylaxine. Summary of product characteristics [Wylaxine. Résumé des caractéristiques du produit]. drive.google.com/file/d/0B2K5buBGjy5rejZjMGRTb0dDTEk/view 2016.
Peppas 2008
    1. Peppas G, Alexiou VG, Mourtzoukou E, Falagas ME. Epidemiology of constipation in Europe and Oceania: a systematic review. BMC Gastroenterology 2008;8:5. - PMC - PubMed
Ramkumar 2005
    1. Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. American Journal of Gastroenterology 2005;100:936-71. - PubMed
Review Manager 2014 [Computer program]
    1. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Romano 2010
    1. Romano M, Cacciatore A, Giordano R, La Rosa B. Postpartum period: three distinct but continuous phases. Journal of Prenatal Medicine 2010;4(2):22–5. - PMC - PubMed
Rungsiprakarn 2015
    1. Rungsiprakarn P, Laopaiboon M, Sangkomkamhang US, Lumbiganon P, Pratt JJ. Interventions for treating constipation in pregnancy. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No: CD011448. [DOI: 10.1002/14651858.CD011448.pub2] - DOI - PMC - PubMed
Schmidt 2014
    1. Schmidt FM, Santos VL. Prevalence of constipation in the general adult population: an integrative review. Journal of Wound, Ostomy, and Continence Nursing 2014;41(1):70-6. - PubMed
Sunitha 2016
    1. Sunitha D, Hemalatha K, Sudhakar M. Banned drugs: a review. Asian Journal of Pharmaceutical Research 2016;6(4):205-16. [DOI: ]
Turawa 2014
    1. Turawa EB, Musekiwa A, Rohwer AC. Interventions for treating postpartum constipation. Cochrane Database of Systematic Reviews 2014, Issue 9. Art. No: CD010273. [DOI: 10.1002/14651858.CD010273.pub2] - DOI - PMC - PubMed
Van Brummen 2006
    1. Van Brummen HJ, Bruinse HW, de Pol G, Heintz AP, Vaart CH. Defecatory symptoms during and after the first pregnancy: prevalences and associated factors. International Urogynecology Journal and Pelvic Floor Dysfunction 2006;17(3):223-4. - PubMed
WHO 1998
    1. World Health Organization, Maternal and Newborn Health/Safe Motherhood Unit. Postpartum care of the mother and newborn: a practical guide. www.who.int/maternal_child_adolescent/documents/who_rht_msm_983/en/ 1998.
WHO 2002
    1. World Health Organization, UNICEF. Breastfeeding and maternal medication: recommendations for drugs in the eleventh WHO model list of essential drugs. www.who.int/maternal_child_adolescent/documents/55732/en/ 2002.
WHO 2010
    1. World Health Organization. WHO technical consultation on postpartum and postnatal care. www.who.int/maternal_child_adolescent/documents/WHO_MPS_10_03/en/ 2010. - PubMed
Xing 2001
    1. Xing JH, Soffer EE. Adverse effects of laxatives. Diseases of the Colon and Rectum 2001;44(8):1201-9. - PubMed
Zainur 2006
    1. Zainur RZ, Loh KY. Postpartum morbidity - what we can do. Medical Journal Malaysia 2006;61:5. - PubMed

References to other published versions of this review

Turawa 2015a
    1. Turawa EB, Musekiwa A, Rohwer AC. Interventions for preventing postpartum constipation. Cochrane Database of Systematic Reviews 2015, Issue 3. Art. No: CD011625. [DOI: 10.1002/14651858.CD011625] - DOI - PMC - PubMed
Turawa 2015b
    1. Turawa EB, Musekiwa A, Rohwer AC. Interventions for preventing postpartum constipation. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No: CD011625. [DOI: 10.1002/14651858.CD011625.pub2] - DOI - PMC - PubMed

Publication types

-